OpenAI said on Tuesday, Oct. 20, 2026, that it has acquired Orchestra Bio , a startup whose platform helps biopharma teams coordinate the work of developing a drug. OpenAI is bringing Orchestra’s team and technology together with Rosalind, its set of AI models and tools for life sciences research. Financial terms were not disclosed, Axios reported ; OpenAI shared the news with the outlet as an exclusive.

Orchestra’s platform handles the coordination work that surrounds the science of drug development. In its announcement, OpenAI said scientists and program leaders on the platform hand the monitoring and tracking of studies and campaigns to AI agents. Its example was a failed manufacturing batch that delays the start of a clinical trial: Orchestra’s agents work out which activities and timelines are affected, pull together the relevant information and compare ways to respond, and people decide what to do next.

The startup put it in similar terms in a note on its own website .…